Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in IgA Nephropathy With High-Grade Proteinuria Across Lee Pathological Grades
ChiCTR2500111301Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Shantou University Medical College
- Start
- Oct 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept in IgA nephropathy (IgAN) (5 arms), sponsored by The Second Affiliated Hospital of Shantou University Medical College. Primary endpoints: Routine urinalysis, Complete Blood Count and 7 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2500111301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111301.